Fig. 4
From: Arbaclofen in fragile X syndrome: results of phase 3 trials
Baseline and end-of-treatment scores (a, c) and change in scores (b, d) for the ABC-FX-Irritability subscale (a, b) and Parenting Stress Index (b, d), in child study for placebo and highest dose (10Â mg TID) arbaclofen groups. Standard error bars represent standard error of the mean